How well do you know about the latest developments in migraine treatment and man...
108 Questions
2 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the aim of the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

  • To develop a cure for migraines
  • To provide a definition of migraines which are difficult-to-treat (correct)
  • To identify all possible preventatives for migraines
  • To establish a new classification system for migraines

    • How many categories of difficult-to-treat migraine were recognized by the EHF Expert Consensus Group?

  • 1
  • 2 (correct)
  • 4
  • 3

    • What is the difference between resistant migraine and refractory migraine according to the EHF Expert Consensus Group?

  • Resistant migraine is less severe than refractory migraine
  • Refractory migraine is less severe than resistant migraine
  • Resistant migraine requires all preventatives to fail, while refractory migraine requires at least 3 classes of preventatives to fail
  • Resistant migraine requires at least 3 classes of preventatives to fail, while refractory migraine requires all preventatives to fail (correct)

    • What is considered debilitating headache according to the EHF Expert Consensus Group?

    <p>Headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    How many triptans need to fail before a patient can be labeled as resistant or refractory according to the EHF Expert Consensus Group?

    <p>2</p> Signup and view all the answers

    What is the minimum follow-up period suggested for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the potential impact of the diagnosis of resistant or refractory migraine on patients?

    <p>It can contribute to stigmatization</p> Signup and view all the answers

    What is the role of comorbidities in the treatment of migraine according to recent research?

    <p>They should be considered in treatment plans</p> Signup and view all the answers

    What is the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health?

    <p>The use of hormonal contraceptives in women with migraine</p> Signup and view all the answers

    What has been shown to be effective in the treatment of chronic migraine according to recent research?

    <p>Behavioral therapy</p> Signup and view all the answers

    What is the impact of the stigma associated with migraine according to recent research?

    <p>It can negatively impact patients' quality of life</p> Signup and view all the answers

    What is the purpose of the global campaign against headache?

    <p>To measure the burden of migraine for clinical management and population-based research</p> Signup and view all the answers

    What is the aim of the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>To provide a definition of migraines which are difficult-to-treat</p> Signup and view all the answers

    How many categories of difficult-to-treat migraine were recognized by the EHF Expert Consensus Group?

    <p>2</p> Signup and view all the answers

    What is the difference between resistant migraine and refractory migraine according to the EHF Expert Consensus Group?

    <p>Resistant migraine requires at least 3 classes of preventatives to fail, while refractory migraine requires all preventatives to fail</p> Signup and view all the answers

    What is considered debilitating headache according to the EHF Expert Consensus Group?

    <p>Headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    How many triptans need to fail before a patient can be labeled as resistant or refractory according to the EHF Expert Consensus Group?

    <p>2</p> Signup and view all the answers

    What is the minimum follow-up period suggested for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the potential impact of the diagnosis of resistant or refractory migraine on patients?

    <p>It can contribute to stigmatization</p> Signup and view all the answers

    What is the role of comorbidities in the treatment of migraine according to recent research?

    <p>They should be considered in treatment plans</p> Signup and view all the answers

    What is the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health?

    <p>The use of hormonal contraceptives in women with migraine</p> Signup and view all the answers

    What has been shown to be effective in the treatment of chronic migraine according to recent research?

    <p>Behavioral therapy</p> Signup and view all the answers

    What is the impact of the stigma associated with migraine according to recent research?

    <p>It can negatively impact patients' quality of life</p> Signup and view all the answers

    What is the purpose of the global campaign against headache?

    <p>To measure the burden of migraine for clinical management and population-based research</p> Signup and view all the answers

    What is the aim of the European Headache Federation consensus document on resistant and refractory migraine?

    <p>To provide a definition of migraines that are difficult-to-treat</p> Signup and view all the answers

    What is the difference between resistant and refractory migraine?

    <p>Resistant migraine has failed all available preventatives, while refractory migraine has failed at least 3 classes of migraine preventatives</p> Signup and view all the answers

    What is the definition of debilitating headache?

    <p>Headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    What is required before a patient can be labeled as resistant or refractory migraine?

    <p>Failure of at least two triptans</p> Signup and view all the answers

    What is the minimum follow-up period suggested for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the implication of introducing the concept of resistant or refractory migraine?

    <p>It will have legal and healthcare implications for patients diagnosed with resistant or refractory migraine</p> Signup and view all the answers

    What is the recommended setting for managing patients with refractory migraine?

    <p>Special interest headache care settings</p> Signup and view all the answers

    What is the focus of the global campaign against headache?

    <p>To develop indices to measure the burden of migraine for clinical management and population-based research</p> Signup and view all the answers

    What is the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health?

    <p>The use of hormonal contraceptives in women with migraine</p> Signup and view all the answers

    What is the recommended approach for patients with chronic migraine who have failed preventive treatments?

    <p>Polytherapy should be considered</p> Signup and view all the answers

    What is the implication of drug misuse in the treatment of drug-induced headache?

    <p>Drug misuse can lead to withdrawal symptoms</p> Signup and view all the answers

    What is the recommended approach for identifying factors that may lead to refractoriness in migraines?

    <p>Central sensitization should be monitored</p> Signup and view all the answers

    What is the aim of the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>To provide a definition of migraines that are difficult-to-treat</p> Signup and view all the answers

    What is the difference between resistant and refractory migraines?

    <p>Resistant migraines have failed all available preventatives, while refractory migraines have failed at least 3 classes of preventatives</p> Signup and view all the answers

    What is considered a debilitating headache according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>Headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    What is the minimum follow-up suggested for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the criteria required before a patient can be labeled as resistant or refractory?

    <p>Failure of at least two triptans</p> Signup and view all the answers

    What is the implication of introducing the concept of resistant and refractory migraine?

    <p>It will have legal and healthcare implications for patients diagnosed with resistant or refractory migraine</p> Signup and view all the answers

    What is the recommended setting for managing patients with resistant migraine?

    <p>Special interest headache care settings</p> Signup and view all the answers

    What is the impact of the stigma associated with migraine?

    <p>It has a negative impact on patients' quality of life</p> Signup and view all the answers

    What is the main purpose of the global campaign against headache?

    <p>To develop indices to measure the burden of migraine for clinical management and population-based research</p> Signup and view all the answers

    What is the recommended duration of follow-up for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the recommended level of care for managing patients with refractory migraine?

    <p>Tertiary level headache clinics</p> Signup and view all the answers

    What is the main reason for establishing drug failure or contraindication in identifying resistant or refractory migraine?

    <p>To identify patients who are drug intolerant</p> Signup and view all the answers

    What is the aim of the European Headache Federation's consensus document on resistant and refractory migraine?

    <p>To provide a definition of migraines that are difficult-to-treat</p> Signup and view all the answers

    What is the difference between resistant migraine and refractory migraine?

    <p>The number of failed preventatives</p> Signup and view all the answers

    What is the definition of 'debilitating headache' according to the European Headache Federation?

    <p>Headache that causes serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    What is the minimum follow-up time suggested for patients with refractory migraine who were never followed by a headache specialist?

    <p>6 months</p> Signup and view all the answers

    What is the main reason for establishing a widely accepted definition of difficult-to-treat migraine?

    <p>To achieve progress in research</p> Signup and view all the answers

    What is the recommended setting for managing patients with resistant migraine?

    <p>Special interest headache care settings</p> Signup and view all the answers

    What is the definition of refractory migraine?

    <p>Having failed all of the available preventatives</p> Signup and view all the answers

    What is the recommended approach to identifying triggers and comorbidities that may contribute to resistant or refractory migraine?

    <p>Identify and manage them before assigning patients to those categories</p> Signup and view all the answers

    What is the definition of 'resistant migraine' according to the European Headache Federation?

    <p>Suffering from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement</p> Signup and view all the answers

    What is the recommended approach to managing patients with refractory migraine?

    <p>Manage their comorbidities before treating their migraines</p> Signup and view all the answers

    What is the recommended approach to assessing the efficacy of acute headache medications?

    <p>Adequate timing of drug administration, dosage, and formulations used should be considered</p> Signup and view all the answers

    What is the recommended approach to identifying factors that may lead to refractoriness in migraine?

    <p>Identify factors such as genetic predisposition, changes in brain structure and function, and mechanisms like central sensitization</p> Signup and view all the answers

    What is the aim of the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>To provide a definition of migraines that are difficult-to-treat</p> Signup and view all the answers

    What process was used to establish definitions in the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>The Delphi method</p> Signup and view all the answers

    What are the two categories of difficult-to-treat migraine recognized by the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>Resistant migraine and refractory migraine</p> Signup and view all the answers

    How is resistant migraine defined according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>Having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement</p> Signup and view all the answers

    How is refractory migraine defined according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>Having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months</p> Signup and view all the answers

    What is the definition of debilitating headache according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>Headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy</p> Signup and view all the answers

    What is the minimum follow-up suggested for patients with refractory migraine who were never followed by a headache specialist according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>6 months</p> Signup and view all the answers

    What are the implications of the diagnosis of resistant or refractory migraine according to the European Headache Federation Consensus on Resistant and Refractory Migraine Definition?

    <p>The concept of resistant or refractory migraine may have profound psychological implications for patients, as it can contribute to stigmatization</p> Signup and view all the answers

    What is the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health according to the text?

    <p>The use of hormonal contraceptives in women with migraine</p> Signup and view all the answers

    What is the impact of the stigma associated with migraine according to the text?

    <p>It can negatively impact patients' quality of life and should be addressed in clinical practice</p> Signup and view all the answers

    What is the aim of the proposed updated European Headache Federation (EHF) definition according to the text?

    <p>To increase understanding of the impact of migraine as a disease with social, legal, and healthcare implications</p> Signup and view all the answers

    What is needed to achieve progress in research, identify underlying mechanisms, and develop evidence-based treatments according to the text?

    <p>A widely accepted definition of difficult-to-treat migraine</p> Signup and view all the answers

    What is the most widely accepted intracranial pressure (ICP) threshold for therapy?

    <p>22 mmHg</p> Signup and view all the answers

    Which group of patients have lower ICP thresholds for prediction of poor outcome?

    <p>Female patients</p> Signup and view all the answers

    What is more important than just targeting an increased ICP in patients with maintained autoregulation?

    <p>Cerebral perfusion pressure (CPP)</p> Signup and view all the answers

    What is the critical threshold for CPP?

    <p>50-60 mmHg</p> Signup and view all the answers

    What is the Lund concept?

    <p>A management strategy for TBI that includes analgosedation, reduction of hydrostatic capillary pressure, and control of fluid balance</p> Signup and view all the answers

    What is the target cerebral perfusion pressure (CPP) used in the Lund concept?

    <p>60-70 mmHg</p> Signup and view all the answers

    What is the fiberoptic catheter that allows for continuous monitoring of the balance between global cerebral oxygen delivery and utilization and reflects cerebral oxygen deficit?

    <p>Jugular venous oximetry (SjVO2)</p> Signup and view all the answers

    What is the critical SjVO2 threshold associated with a poor outcome?

    <p>&lt;55%</p> Signup and view all the answers

    What does brain tissue partial tension of oxygen (PbtO2) provide a continuous measurement of?

    <p>Extracellular oxygen tension as an indicator of the adequacy of oxygen delivery</p> Signup and view all the answers

    What is the proposed algorithm to manage abnormal SjVO2?

    <p>Hypertonic saline therapy</p> Signup and view all the answers

    What is the risk associated with using osmolar agents like hypertonic saline and Na-lactate to reduce ICP?

    <p>Fluid overload including cardiovascular events</p> Signup and view all the answers

    When is decompressive craniectomy (DC) used as a treatment for severe refractory ICP?

    <p>As a last-resort treatment</p> Signup and view all the answers

    What is the most widely accepted intracranial pressure (ICP) threshold for therapy?

    <p>22 mmHg</p> Signup and view all the answers

    What is the critical intracranial pressure (ICP) threshold for predicting poor outcome in older patients (age ≥55 years)?

    <p>18 mmHg</p> Signup and view all the answers

    What is the critical cerebral perfusion pressure (CPP) threshold for TBI patients?

    <p>50-60 mmHg</p> Signup and view all the answers

    Which brain monitoring technique provides continuous measurement of extracellular oxygen tension as an indicator of the adequacy of oxygen delivery?

    <p>Brain tissue partial tension of oxygen</p> Signup and view all the answers

    What is the Lund concept?

    <p>A management strategy for TBI that includes analgosedation, reduction of hydrostatic capillary pressure, and control of fluid balance</p> Signup and view all the answers

    Which gender has a lower intracranial pressure (ICP) threshold for predicting poor outcome?

    <p>Females</p> Signup and view all the answers

    What is the goal of the Lund concept?

    <p>To reduce cerebral blood volume by vasoconstriction</p> Signup and view all the answers

    Which brain monitoring technique allows for continuous monitoring of the balance between global cerebral oxygen delivery and utilization?

    <p>Jugular bulb oximetry</p> Signup and view all the answers

    What is the critical threshold for cerebral perfusion pressure (CPP) in TBI patients with maintained autoregulation?

    <p>50-60 mmHg</p> Signup and view all the answers

    Which therapeutic approach is a last-resort treatment for severe refractory intracranial pressure (ICP)?

    <p>Decompressive craniectomy</p> Signup and view all the answers

    Which brain monitoring technique provides complementary and specific information that allows for selecting the optimal cerebral perfusion pressure (CPP) for the individual patient?

    <p>Brain tissue partial tension of oxygen</p> Signup and view all the answers

    What is the cornerstone of TBI care since the 1980s?

    <p>Intracranial pressure (ICP) monitoring</p> Signup and view all the answers

    What is the most widely accepted intracranial pressure (ICP) threshold for therapy?

    <p>22 mmHg</p> Signup and view all the answers

    What is the critical intracranial pressure (ICP) threshold for predicting poor outcome in older patients (age ≥55 years)?

    <p>18 mmHg</p> Signup and view all the answers

    What is the critical cerebral perfusion pressure (CPP) threshold for TBI patients?

    <p>50-60 mmHg</p> Signup and view all the answers

    Which brain monitoring technique provides continuous measurement of extracellular oxygen tension as an indicator of the adequacy of oxygen delivery?

    <p>Brain tissue partial tension of oxygen</p> Signup and view all the answers

    What is the Lund concept?

    <p>A management strategy for TBI that includes analgosedation, reduction of hydrostatic capillary pressure, and control of fluid balance</p> Signup and view all the answers

    Which gender has a lower intracranial pressure (ICP) threshold for predicting poor outcome?

    <p>Females</p> Signup and view all the answers

    What is the goal of the Lund concept?

    <p>To reduce cerebral blood volume by vasoconstriction</p> Signup and view all the answers

    Which brain monitoring technique allows for continuous monitoring of the balance between global cerebral oxygen delivery and utilization?

    <p>Jugular bulb oximetry</p> Signup and view all the answers

    What is the critical threshold for cerebral perfusion pressure (CPP) in TBI patients with maintained autoregulation?

    <p>50-60 mmHg</p> Signup and view all the answers

    Which therapeutic approach is a last-resort treatment for severe refractory intracranial pressure (ICP)?

    <p>Decompressive craniectomy</p> Signup and view all the answers

    Which brain monitoring technique provides complementary and specific information that allows for selecting the optimal cerebral perfusion pressure (CPP) for the individual patient?

    <p>Brain tissue partial tension of oxygen</p> Signup and view all the answers

    What is the cornerstone of TBI care since the 1980s?

    <p>Intracranial pressure (ICP) monitoring</p> Signup and view all the answers

    Study Notes

    European Headache Federation Consensus on Resistant and Refractory Migraine Definition

    • Some patients with migraine do not experience adequate pain relief with acute and preventive treatments.

    • The aim of the document is to provide a definition of those migraines which are difficult-to-treat.

    • The consensus process using the Delphi method was used to establish definitions.

    • Two categories of difficult-to-treat migraine were recognized, resistant migraine and refractory migraine.

    • Resistant migraine is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement.

    • Refractory migraine is defined by having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months.

    • Drug failure may include lack of efficacy or lack of tolerability.

    • Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy.

    • Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved.

    • It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

    • Triggers and comorbidities which may contribute to resistant or refractory migraine need to be identified and managed before assigning patients to those categories.

    • Careful differential diagnosis with mimicking conditions must be done.Proposed Criteria for Resistant or Refractory Migraine

    • A patient with >50% reduction in headache days with treatment may be labeled as resistant or refractory.

    • The criteria proposed by the EHF Expert Consensus Group rely on the presence of a given number of days of debilitating headache attacks.

    • Adequate timing of drug administration, dosage, and formulations used should be considered when assessing the efficacy of acute headache medications.

    • The EHF Expert Consensus Group did not choose to use cut scores at common validated instruments to measure function or disability.

    • Failure of at least two triptans is required before a patient can be labeled as resistant or refractory.

    • Establishing drug failure or contraindication is pivotal to identifying resistant or refractory migraine.

    • Patients suffering from migraine frequently have comorbid disorders that should be addressed and managed before labeling them as resistant or refractory.

    • Differential diagnosis should be considered to rule out other primary or secondary headaches that may entirely account for the clinical picture or coexist with migraine.

    • The present definition did not consider failure to devices or nonpharmacological therapies.

    • Patients with resistant migraine should be managed in special interest headache care settings, and patients with refractory migraine must be managed in tertiary level headache clinics.

    • Establishing previous treatment failures should be done by chart review, and information on duration, dose, and adverse events should be reliable.

    • A minimum follow-up of 6 months is suggested for patients with refractory migraine who were never followed by a headache specialist.Implications and Future Perspectives of the Diagnosis of Resistant or Refractory Migraine

    • The diagnosis of resistant or refractory migraine is a serious matter that requires careful establishment.

    • The concept of resistant or refractory migraine may have profound psychological implications for patients, as it can contribute to stigmatization.

    • Education and effort are needed to help patients and physicians understand the possible fluctuations of the disease.

    • There could be legal and healthcare implications for patients diagnosed with resistant or refractory migraine, such as access to newer treatments or social welfare.

    • The introduction of the concept of resistant and refractory migraine will have clinical and political implications, and operational criteria are needed to define these subpopulations.

    • The proposed updated European Headache Federation (EHF) definition identifies two subsets of difficult-to-treat migraine: resistant and refractory migraine, and considers both frequency and disability from single and frequent attacks.

    • The proposed criteria will allow inclusion of new migraine preventive treatments when there is good evidence for their use.

    • Reliable criteria are needed to identify factors that may lead to refractoriness, such as genetic predisposition, changes in brain structure and function, and mechanisms like central sensitization.

    • Field-testing of the proposed updated EHF definition is needed to identify possible deficiencies and make further improvements, and adaptations at the country level may be necessary to make the definition more usable.

    • A widely accepted definition of difficult-to-treat migraine is necessary to achieve progress in research, identify underlying mechanisms, and develop evidence-based treatments.

    • The proposed updated EHF definition aims to increase understanding of the impact of migraine as a disease with social, legal, and healthcare implications.

    • The EHF Expert Consensus Group hopes that the proposed criteria will stimulate further clinical, scientific, and social attention to patients who suffer from difficult-to-treat migraine.Key Points from Recent Research on Migraine

    • Multiple studies have been conducted on the use of onabotulinumtoxinA and monoclonal antibodies for the prevention of chronic migraine.

    • Clinical trials have shown that triptan nonresponders exist and may benefit from alternative treatments, such as polytherapy.

    • Comorbidities, including sleep disturbances and cardiovascular diseases, are common in migraine patients and should be considered in treatment plans.

    • The American Headache Society and the European Federation of Neurological Societies have issued guidelines on the drug treatment of migraine and integrating new treatments into clinical practice.

    • The use of hormonal contraceptives in women with migraine has been the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health.

    • Behavioral therapy has been shown to be effective in the treatment of chronic migraine.

    • The development of national migraine strategies, such as in Canada, can help improve the management of migraine and reduce healthcare costs.

    • The stigma associated with migraine can negatively impact patients' quality of life and should be addressed in clinical practice.

    • Patients with chronic migraine who have failed preventive treatments experience a high disease burden and reduced quality of life.

    • Acute migraine treatment options have been assessed and evaluated by the American Headache Society.

    • The global campaign against headache has developed indices to measure the burden of migraine for clinical management and population-based research.

    • Withdrawal therapy and drug misuse can be a concern in the treatment of drug-induced headache.

    European Headache Federation Consensus on Resistant and Refractory Migraine Definition

    • Some patients with migraine do not experience adequate pain relief with acute and preventive treatments.

    • The aim of the document is to provide a definition of those migraines which are difficult-to-treat.

    • The consensus process using the Delphi method was used to establish definitions.

    • Two categories of difficult-to-treat migraine were recognized, resistant migraine and refractory migraine.

    • Resistant migraine is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement.

    • Refractory migraine is defined by having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months.

    • Drug failure may include lack of efficacy or lack of tolerability.

    • Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy.

    • Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved.

    • It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

    • Triggers and comorbidities which may contribute to resistant or refractory migraine need to be identified and managed before assigning patients to those categories.

    • Careful differential diagnosis with mimicking conditions must be done.Proposed Criteria for Resistant or Refractory Migraine

    • A patient with >50% reduction in headache days with treatment may be labeled as resistant or refractory.

    • The criteria proposed by the EHF Expert Consensus Group rely on the presence of a given number of days of debilitating headache attacks.

    • Adequate timing of drug administration, dosage, and formulations used should be considered when assessing the efficacy of acute headache medications.

    • The EHF Expert Consensus Group did not choose to use cut scores at common validated instruments to measure function or disability.

    • Failure of at least two triptans is required before a patient can be labeled as resistant or refractory.

    • Establishing drug failure or contraindication is pivotal to identifying resistant or refractory migraine.

    • Patients suffering from migraine frequently have comorbid disorders that should be addressed and managed before labeling them as resistant or refractory.

    • Differential diagnosis should be considered to rule out other primary or secondary headaches that may entirely account for the clinical picture or coexist with migraine.

    • The present definition did not consider failure to devices or nonpharmacological therapies.

    • Patients with resistant migraine should be managed in special interest headache care settings, and patients with refractory migraine must be managed in tertiary level headache clinics.

    • Establishing previous treatment failures should be done by chart review, and information on duration, dose, and adverse events should be reliable.

    • A minimum follow-up of 6 months is suggested for patients with refractory migraine who were never followed by a headache specialist.Implications and Future Perspectives of the Diagnosis of Resistant or Refractory Migraine

    • The diagnosis of resistant or refractory migraine is a serious matter that requires careful establishment.

    • The concept of resistant or refractory migraine may have profound psychological implications for patients, as it can contribute to stigmatization.

    • Education and effort are needed to help patients and physicians understand the possible fluctuations of the disease.

    • There could be legal and healthcare implications for patients diagnosed with resistant or refractory migraine, such as access to newer treatments or social welfare.

    • The introduction of the concept of resistant and refractory migraine will have clinical and political implications, and operational criteria are needed to define these subpopulations.

    • The proposed updated European Headache Federation (EHF) definition identifies two subsets of difficult-to-treat migraine: resistant and refractory migraine, and considers both frequency and disability from single and frequent attacks.

    • The proposed criteria will allow inclusion of new migraine preventive treatments when there is good evidence for their use.

    • Reliable criteria are needed to identify factors that may lead to refractoriness, such as genetic predisposition, changes in brain structure and function, and mechanisms like central sensitization.

    • Field-testing of the proposed updated EHF definition is needed to identify possible deficiencies and make further improvements, and adaptations at the country level may be necessary to make the definition more usable.

    • A widely accepted definition of difficult-to-treat migraine is necessary to achieve progress in research, identify underlying mechanisms, and develop evidence-based treatments.

    • The proposed updated EHF definition aims to increase understanding of the impact of migraine as a disease with social, legal, and healthcare implications.

    • The EHF Expert Consensus Group hopes that the proposed criteria will stimulate further clinical, scientific, and social attention to patients who suffer from difficult-to-treat migraine.Key Points from Recent Research on Migraine

    • Multiple studies have been conducted on the use of onabotulinumtoxinA and monoclonal antibodies for the prevention of chronic migraine.

    • Clinical trials have shown that triptan nonresponders exist and may benefit from alternative treatments, such as polytherapy.

    • Comorbidities, including sleep disturbances and cardiovascular diseases, are common in migraine patients and should be considered in treatment plans.

    • The American Headache Society and the European Federation of Neurological Societies have issued guidelines on the drug treatment of migraine and integrating new treatments into clinical practice.

    • The use of hormonal contraceptives in women with migraine has been the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health.

    • Behavioral therapy has been shown to be effective in the treatment of chronic migraine.

    • The development of national migraine strategies, such as in Canada, can help improve the management of migraine and reduce healthcare costs.

    • The stigma associated with migraine can negatively impact patients' quality of life and should be addressed in clinical practice.

    • Patients with chronic migraine who have failed preventive treatments experience a high disease burden and reduced quality of life.

    • Acute migraine treatment options have been assessed and evaluated by the American Headache Society.

    • The global campaign against headache has developed indices to measure the burden of migraine for clinical management and population-based research.

    • Withdrawal therapy and drug misuse can be a concern in the treatment of drug-induced headache.

    European Headache Federation Consensus on Resistant and Refractory Migraine Definition

    • Some patients with migraine do not experience adequate pain relief with acute and preventive treatments.

    • The aim of the document is to provide a definition of those migraines which are difficult-to-treat.

    • The consensus process using the Delphi method was used to establish definitions.

    • Two categories of difficult-to-treat migraine were recognized, resistant migraine and refractory migraine.

    • Resistant migraine is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement.

    • Refractory migraine is defined by having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months.

    • Drug failure may include lack of efficacy or lack of tolerability.

    • Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy.

    • Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved.

    • It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

    • Triggers and comorbidities which may contribute to resistant or refractory migraine need to be identified and managed before assigning patients to those categories.

    • Careful differential diagnosis with mimicking conditions must be done.Proposed Criteria for Resistant or Refractory Migraine

    • A patient with >50% reduction in headache days with treatment may be labeled as resistant or refractory.

    • The criteria proposed by the EHF Expert Consensus Group rely on the presence of a given number of days of debilitating headache attacks.

    • Adequate timing of drug administration, dosage, and formulations used should be considered when assessing the efficacy of acute headache medications.

    • The EHF Expert Consensus Group did not choose to use cut scores at common validated instruments to measure function or disability.

    • Failure of at least two triptans is required before a patient can be labeled as resistant or refractory.

    • Establishing drug failure or contraindication is pivotal to identifying resistant or refractory migraine.

    • Patients suffering from migraine frequently have comorbid disorders that should be addressed and managed before labeling them as resistant or refractory.

    • Differential diagnosis should be considered to rule out other primary or secondary headaches that may entirely account for the clinical picture or coexist with migraine.

    • The present definition did not consider failure to devices or nonpharmacological therapies.

    • Patients with resistant migraine should be managed in special interest headache care settings, and patients with refractory migraine must be managed in tertiary level headache clinics.

    • Establishing previous treatment failures should be done by chart review, and information on duration, dose, and adverse events should be reliable.

    • A minimum follow-up of 6 months is suggested for patients with refractory migraine who were never followed by a headache specialist.Implications and Future Perspectives of the Diagnosis of Resistant or Refractory Migraine

    • The diagnosis of resistant or refractory migraine is a serious matter that requires careful establishment.

    • The concept of resistant or refractory migraine may have profound psychological implications for patients, as it can contribute to stigmatization.

    • Education and effort are needed to help patients and physicians understand the possible fluctuations of the disease.

    • There could be legal and healthcare implications for patients diagnosed with resistant or refractory migraine, such as access to newer treatments or social welfare.

    • The introduction of the concept of resistant and refractory migraine will have clinical and political implications, and operational criteria are needed to define these subpopulations.

    • The proposed updated European Headache Federation (EHF) definition identifies two subsets of difficult-to-treat migraine: resistant and refractory migraine, and considers both frequency and disability from single and frequent attacks.

    • The proposed criteria will allow inclusion of new migraine preventive treatments when there is good evidence for their use.

    • Reliable criteria are needed to identify factors that may lead to refractoriness, such as genetic predisposition, changes in brain structure and function, and mechanisms like central sensitization.

    • Field-testing of the proposed updated EHF definition is needed to identify possible deficiencies and make further improvements, and adaptations at the country level may be necessary to make the definition more usable.

    • A widely accepted definition of difficult-to-treat migraine is necessary to achieve progress in research, identify underlying mechanisms, and develop evidence-based treatments.

    • The proposed updated EHF definition aims to increase understanding of the impact of migraine as a disease with social, legal, and healthcare implications.

    • The EHF Expert Consensus Group hopes that the proposed criteria will stimulate further clinical, scientific, and social attention to patients who suffer from difficult-to-treat migraine.Key Points from Recent Research on Migraine

    • Multiple studies have been conducted on the use of onabotulinumtoxinA and monoclonal antibodies for the prevention of chronic migraine.

    • Clinical trials have shown that triptan nonresponders exist and may benefit from alternative treatments, such as polytherapy.

    • Comorbidities, including sleep disturbances and cardiovascular diseases, are common in migraine patients and should be considered in treatment plans.

    • The American Headache Society and the European Federation of Neurological Societies have issued guidelines on the drug treatment of migraine and integrating new treatments into clinical practice.

    • The use of hormonal contraceptives in women with migraine has been the subject of consensus statements from the European Headache Federation and the European Society of Contraception and Reproductive Health.

    • Behavioral therapy has been shown to be effective in the treatment of chronic migraine.

    • The development of national migraine strategies, such as in Canada, can help improve the management of migraine and reduce healthcare costs.

    • The stigma associated with migraine can negatively impact patients' quality of life and should be addressed in clinical practice.

    • Patients with chronic migraine who have failed preventive treatments experience a high disease burden and reduced quality of life.

    • Acute migraine treatment options have been assessed and evaluated by the American Headache Society.

    • The global campaign against headache has developed indices to measure the burden of migraine for clinical management and population-based research.

    • Withdrawal therapy and drug misuse can be a concern in the treatment of drug-induced headache.

    Therapeutic Approaches for Traumatic Brain Injury: Intracranial Pressure and Cerebral Perfusion Pressure

    • A significant number of patients with severe TBI develop raised intracranial pressure (ICP) depending on intracranial lesion, age, and definition.

    • The most widely accepted ICP threshold for therapy is 20 mmHg, although the latest guidelines suggest 22 mmHg.

    • Critical ICP thresholds may vary between young and old and male and female patients, with older patients (age ≥55 years) and females having lower ICP thresholds (18 mmHg vs. 22 mmHg) for prediction of poor outcome.

    • Intracranial pressure monitoring has been the cornerstone of TBI care since the 1980s, although a multicenter trial did not show superiority of management using continuous measurement of ICP compared to repeated clinical examination and CT scans.

    • Cerebral perfusion pressure (CPP) is more important than just targeting an increased ICP, particularly in patients with maintained autoregulation.

    • Critical threshold for CPP lies between 50 and 60 mmHg, and brain monitoring techniques such as jugular venous oximetry, monitoring of brain tissue oxygen tension (PbtO2), and cerebral microdialysis could provide complementary and specific information that allows for selecting the optimal CPP for the individual patient.

    • The latest guidelines suggest discrimination between individuals with and without preserved autoregulation.

    • CPP-targeted treatment concept includes basic measures, active interventions, and aggressive treatment of refractory elevated intracranial pressure.

    • The Lund concept, an ICP and volume targeted concept, focuses on the reduction of ICP by decreasing intracranial volumes.

    • The goals of the Lund concept are to preserve a normal colloid osmotic pressure, reduce capillary hydrostatic pressure, and reduce cerebral blood volume by vasoconstriction.

    • Osmolar agents like hypertonic saline and Na-lactate are effective in reducing ICP, but evidence for improved neurological outcome for all these interventions is still very limited and they bear a risk of fluid overload including cardiovascular events and risks of osmotic diuresis, including dehydration.

    • Decompressive craniectomy (DC) for selected cases only as DC is a last-resort treatment for severe refractory ICP, reducing ICP and mortality while increasing incidence of unfavorable outcome at six months.Advanced Management Strategies for Traumatic Brain Injury: Bedside Physiological Monitoring and Tailored Therapy

    • The Lund concept is a management strategy for traumatic brain injury (TBI) that includes analgosedation, reduction of hydrostatic capillary pressure, and control of fluid balance.

    • The Lund concept has not been widely accepted outside of Sweden due to limited evidence of superiority compared to other treatments and controversial issues.

    • A target cerebral perfusion pressure (CPP) of 60-70 mmHg is used in the Lund concept, which contradicts the common treatment goal of cerebral blood flow optimization by augmentation of CPP.

    • Advanced bedside physiological monitoring techniques can provide more precise understanding of the influencing factors of TBI and allow for better-tailored therapies.

    • Increased intracranial pressure (ICP) is not a diagnosis by itself but rather a symptom resulting from different processes, including intracranial mass lesions, increased cerebral blood volume, brain edema, and impaired cerebrospinal fluid reabsorption.

    • Jugular bulb oximetry (SjVO2) is a fiberoptic catheter that allows for continuous monitoring of the balance between global cerebral oxygen delivery and utilization and reflects cerebral oxygen deficit.

    • SjVO2 has a prognostic value, and a decrease in SjVO2 below 55% is associated with a poor outcome.

    • Brain tissue partial tension of oxygen (PbtO2) provides a continuous measurement of extracellular oxygen tension as an indicator of the adequacy of oxygen delivery.

    • Reduced PbtO2 has been associated with a poor outcome after neurotrauma.

    • Oxygen diffusion can modulate PbtO2, which can be further modulated in pericontusional tissue.

    • Advanced bedside physiological monitoring techniques include autoregulation assessment, continuous electroencephalography (EEG) or its surrogate bispectral index (BIS), and different imaging modalities (e.g., transcranial doppler ultrasound).

    • A proposed algorithm to manage abnormal SjVO2 includes hypertonic saline therapy. However, SjVO2 measurement is not used frequently in clinical routine due to technical reasons.

    Management of Traumatic Brain Injury: Intracranial Pressure Monitoring and Cerebral Perfusion Pressure Guided Therapy

    • A significant number of severe TBI patients develop raised intracranial pressure (ICP), with the most widely accepted threshold for therapy being 20 mmHg.

    • Critical ICP thresholds may vary between young and old and male and female patients, with older patients (age ≥55 years) and females having lower ICP thresholds (18 mmHg vs. 22 mmHg) for prediction of poor outcome.

    • ICP monitoring is indicated in patients with severe TBI (GCS ≤8) and protocols for ICP therapy vary in detail and are mainly based on experience and consensus guidelines.

    • Targeting cerebral perfusion pressure (CPP) as a surrogate for relative cerebral perfusion is more important than just targeting an increased ICP, especially in patients with maintained autoregulation.

    • The optimal level of CPP is uncertain, but a CPP above 70 mmHg should be avoided due to the risk of acute respiratory distress syndrome (ARDS).

    • A low CPP causes a reduction in cerebral blood flow (CBF) and may induce an elevation in cerebral blood volume (CBV) and thus ICP within the range of autoregulation, predisposing the injured brain to cerebral ischemia and infarction.

    • The critical threshold for CPP lies between 50 and 60 mmHg, but brain monitoring techniques such as jugular venous oximetry (SvJO2), monitoring of brain tissue oxygen tension (PbtO2), and cerebral microdialysis could provide complementary and specific information that allows for selecting the optimal CPP for the individual patient.

    • The CPP-targeted treatment concept includes basic measures such as analgosedation, normocapnic mechanical ventilation, normovolemia, and maintenance of a cerebral perfusion pressure of 60-70 mmHg if autoregulation is preserved.

    • Aggressive treatment of refractory elevated intracranial pressure includes metabolic suppression (e.g., burst suppression targeted EEG-guided barbiturate coma), hypothermia, decompressive craniectomy (DC), and hypnocapnic ventilation (rescue therapy only).

    • The Lund concept is a therapeutic approach that focuses on the reduction of ICP by decreasing intracranial volumes, emphasizing a reduction in microvascular pressures to minimize cerebral edema formation.

    • The goals of the Lund concept include preserving a normal colloid osmotic pressure by infusion of albumin and correction of anemia, reducing capillary hydrostatic pressure by medical control of blood pressure, and reducing cerebral blood volume by vasoconstriction.

    • Osmolar agents such as NaCl 7.5%, hypertonic saline (HTS), and Mannitol are effective in reducing ICP but bear a risk of fluid overload including cardiovascular events and risks of osmotic diuresis, including dehydration. Evidence forAdvanced Bedside Physiological Monitoring for Tailored Management of Cerebral Perfusion Pressure in Traumatic Brain Injury

    • The Lund concept for Traumatic Brain Injury (TBI) management includes reduction of stress and brain metabolism, reduction of hydrostatic capillary pressure, and maintenance of colloid-oncotic pressure.

    • The Lund concept has not been compared to other treatments in larger studies, but small randomized trials have shown superior outcomes.

    • The Lund approach contradicts common treatment goals of cerebral blood flow optimization by augmentation of cerebral perfusion pressure.

    • Use of microdialysis, jugular venous oximetry, and brain tissue oxygen saturation (PbO2) can provide more detailed identification of pathophysiological derangements in TBI patients.

    • Jugular Bulb Oximetry (SjVO2) allows for estimation of the balance between global cerebral oxygen delivery and utilization and reflects cerebral oxygen deficit.

    • Continuous monitoring of SjVO2 helps to determine the optimal cerebral perfusion pressure (CPP) required for the maintenance of cerebral oxygenation.

    • Brain Tissue Partial Tension of Oxygen (PbtO2) provides a continuous measurement of extracellular oxygen tension as an indicator of the adequacy of oxygen delivery.

    • Normal PbtO2 is in the range of 35-50 mmHg, and reduced PbtO2 has been associated with a poor outcome after neurotrauma.

    • Ischemic thresholds between 5-20 mmHg have been suggested for PbtO2.

    • SjVO2 has a prognostic value, and a decrease below 55% is associated with a poor outcome.

    • The use of albumin and steroids contradicts findings in the SAFE and CRASH trials, respectively.

    • SjVO2 measurement is cumbersome, and PbtO2 provides a localized measurement of extracellular oxygen tension with limited sensitivity to regional changes.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    EHF 2020 Consensus on Resistant & Refractory Migraine PDF

    Description

    Test your knowledge on the latest European Headache Federation Consensus on Resistant and Refractory Migraine Definition and recent research on migraine. This quiz will cover the criteria for labeling migraines as resistant or refractory, the implications and future perspectives of the diagnosis, and key points from recent research. Challenge yourself to see how much you know about this important topic and stay up-to-date on the latest developments in migraine treatment and management.

    More Like This

    Migraine Prophylaxis and Comorbidities Quiz
    5 questions

    Migraine Prophylaxis and Comorbidities Quiz

    FineSpring4688 avatar
    FineSpring4688
    Treatment for Migraine Attacks Quiz
    29 questions

    Treatment for Migraine Attacks Quiz

    FlawlessNourishment avatar
    FlawlessNourishment
    Migraine Pathogenesis and Symptoms
    40 questions

    Migraine Pathogenesis and Symptoms

    StimulativeMarigold5381 avatar
    StimulativeMarigold5381
    Migraine - A Complex Disease and Treatment
    37 questions

    Migraine - A Complex Disease and Treatment

    CorrectJasper802 avatar
    CorrectJasper802
    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser